What are the ACR treatment guidelines for gout in patients with renal disease?

Updated: Jan 26, 2021
  • Author: Bruce M Rothschild, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

In patients with gout who have moderate to severe kidney disease, ACR guidelines recommend xanthine oxidase inhibitor therapy with either allopurinol or febuxostat as the first-line pharmacologic approach. Probenecid can be used in patients who have contraindications to or are intolerant of at least 1 of those first-line agents, or it may be combined with a xanthine oxidase inhibitor if the inhibitor does not lower uric acid sufficiently. [125, 127]  Probenecid could also be used for those patients who consider the risks of xanthine oxidase inhibitors to be too high.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!